Amphastar Pharmaceuticals, Inc. (AMPH) Earnings Call Analysis

NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic

20/25

Growth 5 Margin 4 Expansion 5 Platform 1 Financial 5

latest quarter score

Earnings Reports

20
Amphastar (AMPH) Q2 2026: New Generics Add $8.4M as Margin Mix Shifts Amid IMS Remediation
August 07, 2026
14
Amphastar (AMPH) Q1 2026: New Launches Offset 15% Baximi Price Hit as Portfolio Mix Shifts
May 08, 2026
10
Amphastar (AMPH) Q4 2025: Ipratropium Bromide HFA Approval Unlocks 180 Days of Market Exclusivity
February 27, 2026
12
Amphastar (AMPH) Q3 2025: Proprietary Pipeline Now 50% of R&D, Pushing $60B Market Expansion
November 07, 2025
12
Amphastar Pharmaceuticals (AMPH) Q2 2025: BAQSIMI Sales Surge 21% Amid Capacity Expansion Plans
August 07, 2025
10
Amphastar Pharmaceuticals (AMPH) Q1 2025: BAQSIMI Sales Surge 177% Amid Competitive Pressures
May 07, 2025
Amphastar (AMPH) Q3 2024: Gross Margin Slides 700bps as Baximi Transition Reshapes P&L
November 06, 2024
Amphastar (AMPH) Q2 2024: Gross Margin Lifts to 52.2% as Baximi and Epinephrine Outperform
August 07, 2024
Amphastar (AMPH) Q1 2024: Baximi Sales Jump 22% as Portfolio Integration Drives Expansion
May 08, 2024
14
Amphastar (AMPH) Q3 2023: Gross Margin Hits 60% as Shortage Response and Baximi Shift Portfolio Leverage
November 08, 2023
Amphastar (AMPH) Q2 2023: Glucagon Sales Double, Drug Shortages Drive 47% Surge in Hospital Products
August 08, 2023
Amphastar (AMPH) Q1 2023: Glucagon Sales Surge 134% Fuels High-Margin Momentum and Diabetes Expansion
May 09, 2023
Amphastar (AMPH) Q4 2022: Gross Margin Hits 53% as High-Margin Portfolio Drives Profit Expansion
February 28, 2023

Browse all companies